Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Expedia Group Inc (EXPE) Price & Performance

Quest Diagnostics IncTrade
Expedia Group IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Expedia Group Inc — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while Expedia Group Inc trades at $270.23 (market cap $32.42B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Expedia Group Inc for 48 Days on average.

DGXEXPE
Market Cap
$25.48B$32.42B
Volume
941,8661,940,671
Sector
HealthConsumer Cyclical
52-Week High
$247.45$339.13
52-Week Low
$173.49$188.51
Typical Hold Time
56 Days48 Days
Enterprise Value
$31.23B$30.98B
Dividend Yield
1.49%0.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.

DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.

Expedia Group Inc

Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, amid a bearish technical signal and recent news-driven volatility. The stock shows strong fundamentals with consistent earnings beats, revenue growth to $14.73B in 2025, and robust profitability margins. Recent layoffs and competitive threats from AI travel agents have pressured sentiment, but analyst consensus remains largely positive with a $335.06 price target.

The outlook balances solid financial health and attractive valuation against near-term competitive and execution risks. Upside potential exists if Expedia navigates AI disruption and sustains booking growth, but investor caution is warranted given technical weakness and industry headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DGX

No sentiment data available yet.

EXPE
100% Buy0% Sell
Avg holding period · 48 Days

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →

About Expedia Group Inc

Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.

Read more on EXPE →